Clinical Trial

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to provide continued access to GLM101 to treat PMM2-CDG in people who have previously received GLM101 in other trials and learn about the long term effect of GLM101. Participants will complete weekly infusions of GLM101 at the same dose level received in previous trials.
Protocol Amendment History 1 change
notable Trial sites expanded: 2 -> 15 locations 2026-07-07
Trial Details
NCT Number NCT06657859
Lead Sponsor Glycomine, Inc.
Conditions Pmm2-CDG, Phosphomannomutase 2 Deficiency
Enrollment 90 participants
Start Date 2024-09-30
Primary Completion 2029-09 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-28